1 Guidance

1 Guidance

1.1 Dapagliflozin in a dual therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if:

  • a sulfonylurea is contraindicated or not tolerated or

  • the person is at significant risk of hypoglycaemia or its consequences.

1.2 Dapagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an option for treating type 2 diabetes.

1.3 This recommendation has been updated and replaced by NICE's technology appraisal guidance on dapagliflozin in triple therapy for treating type 2 diabetes.

1.4 People currently receiving dapagliflozin in a dual therapy regimen that is not recommended for them in 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.

  • National Institute for Health and Care Excellence (NICE)